According to Zhitong Finance App, Fengyuan Pharmaceutical (000153.SZ) issued an announcement. Recently, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for vonoracin fumarate tablets (20mg, 10mg) approved and issued by the State Drug Administration. Voronolacin fumarate is a potassium ion competitive acid blocker (P-CAB for short), which can inhibit gastric acid production and damage to the upper gastrointestinal mucosa. It is mainly used to treat reflux esophagitis and Helicobacter pylori infection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.